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gender, ethnicity, marital status, educational attainment, household income, em-
ployment status, insurance possession, body mass index, exercise and smoking
habits, alcohol use, and HIV/AIDS and hepatitis B status as predictors. RESULTS:
Mean age was similar between hepatitis C patients who had ever initiated treat-
ment (51.3 yrs, SD11.39) and thosewho had not (52.0 yrs, SD11.50). Patients who
were married (OR1.43, p.004), in possession of insurance (OR1.56, p.003), or
diagnosed with AIDS or HIV (OR1.60, p.05) were more likely to have initiated
treatment than patients without those characteristics. No other significant differ-
ences were found. CONCLUSIONS: The current findings indicate that lack of insur-
ance and lack of support from a partner are associatedwith lower odds of initiating
treatment for hepatitis C. While speculative, this suggests that lack of social sup-
port and insurance may be barriers to treatment. Patients treated for hepatitis C
may be more informed about their HIV/AIDS status, although conversely, patients
with HIV/AIDS may be more likely to initiate therapy to avoid liver-related immu-
nodeficiency complications. Further investigation is needed to help determine the
direction of causation.
PGI5
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OBJECTIVES: To compare health care utilizations between patients who switched
from a branded proton pump inhibitor (PPI) to a generic PPI and vice versa.
METHODS:We conducted a retrospective database analysis using commercial en-
rollees froma largeUShealth plan fromFebruary 2008 toMarch 2010. Continuously
eligible adult patients who had gastroesophageal reflux disease (GERD) or GERD-
related conditions, and evidence of PPI use during February 2009 to September 2009
were included. The index PPI was defined as the first PPI prescribed during the
identification period. Patients who switched from a generic PPI to a branded index
PPI and patientswho switched froma branded index PPI to a generic index PPIwere
included as the two cohorts in this study. Risk adjustment was performed using
propensity score matching. We controlled for age, gender, region, GERD severity,
plan, pre-index Quan-Charlson comorbidity score (CCI), baseline DACON, and
baseline costs and utilization. RESULTS: A total of 9881 patients from each cohort
were matched after propensity score matching. During the six months after the
switch, therewere no significant differences in office visits, emergency roomvisits,
and inpatients admission rates between the two groups of switchers. Patients who
switched from a branded PPI to a generic PPI had a slightly lower rate of outpatient
visits compared to patients who switched from a generic PPI to a branded PPI
(54.67% vs. 56.23%, p0.0275). CONCLUSIONS:Although outpatient visit rates were
slightly lower for patientswho switched froma branded to a generic PPI, therewere
no significant differences in other health care utilizations such as office visits,
emergency room visits, and inpatient admissions.
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OBJECTIVES: Untreated chronic hepatitis C (HCV) may progress to advanced liver
disease (ALD), including decompensated cirrhosis (DC) and/or hepatocellular car-
cinoma (HCC). ALD can lead to significant clinical and economic consequences,
including liver transplantation. There are limited data on ALD-associated health-
care costs among HCV-infected patients in a Medicaid program.METHODS: Using
Florida Medicaid administrative claims data, we identified cases with HCV diagno-
sis on an inpatient or outpatient claim, or prescription HCV therapy, with an inci-
dent ALD-related diagnosis (“index event”) between 7/1/1999 and 6/30/2007. ALD-
related conditions included DC, HCC, or liver transplant procedure or history.
Patients were included if they had11months continuousMedicaid eligibility pre-
and post-index, and no enrollment in Medicare or an HMO. A one-to-one matched
control cohort of HCV cases without ALD was generated using age, sex, and race.
2009 USD per-patient-per-month (PPPM) costs were reported and compared be-
tween cases and controls usingWilcoxon rank sum tests. RESULTS: The final study
group included 1,193 cases and 1,193 matched controls (mean age: 49 years; 45%
female; 54% white, 23% black, 23% other). The majority of ALD-related diagnoses
were DC (92%), followed by HCC (6%) and liver transplant (2%). Cases with ALD had
greater comorbidity (mean Charlson score: 3.1 vs. 2.3 among controls, P.001).
All-cause inpatient resource use in the one year follow-up from incident ALD di-
agnosis was significantly greater among cases than controls (74% vs. 27%, P.001).
Mean all-cause PPPM costs (including inpatient, outpatient, pharmacy, and others)
were 3 times greater among cases with ALD than controls ($4,937 vs $1,730,
P.001). CONCLUSIONS: HCV patients with ALD had a 2.9-fold higher economic
burden in Florida Medicaid from 7/99 to 6/07 than the controls in the first year
following ALD development. Preventing or delaying ALD onset in HCV patients
could potentially help reduce this economic burden. Further study is necessary.
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OBJECTIVES: Gastroesophogeal reflux disease (GERD) is a common disease affect-
ing 10-20% of the US adult population. The objective of this study was to estimate
the prevalence of refractory GERD and associated direct medical costs using real-
world data.METHODS: Adult patients with GERD initiating a GERDmedication were
identified using theMarketScan Research Databases (2004-2009) and evaluated in the
twelve months before and after GERD medication initiation. Refractory GERD was
evaluated using an eight point scalewhere one pointwas given for each of the follow-
ing: doubling GERD medication dose (including BID), adding another GERD medica-
tion, switchingGERDmedications, GERD-related procedure receipt, GERD-related sur-
gery receipt, excess GI-related outpatient visits (2), excess GERD-related office visits
(2), or GI-related ER visits. Patients were determined to have refractory GERD if they
had 2 or more points. Annual unadjusted and multivariate adjusted GERD-related
costs (i.e., claims with a GERD diagnosis) and all-cause costs were reported in 2009
dollars for patients with and without refractory GERD. RESULTS: A total of 135,139
GERD patientswere analyzed (mean age 52.9 (SD14.5) years, 44%male). Approx-
imately one-third (31%) of patients had refractory GERD. Versus patients with non-
refractory GERD, refractory GERD patients were more likely to be female (59% vs.
55%, p0.001) and had a higher Deyo Charlson Comorbidity score after GERDmed-
ication initiation (0.78 vs. 0.56, p 0.001); average age was similar in both groups.
Compared to non-refractory GERD patients, refractory GERD patients had higher
total all-cause costs ($18,088 (SD$36,220) versus $11,044 ($22,985), p0.001) and
higher GERD-related costs ($2,022 (SD$2,236) versus $1,172 (SD$1,117), p0.001).
After controlling for demographic and clinical characteristics, refractory GERDwas
associated with an additional $7,089 (SD$7,705) in total costs and $845 (SD$111)
in GERD-related costs. CONCLUSIONS: Refractory GERD is a common disease that
may be associatedwith increasedmedical resource utilization and associated cost.
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OBJECTIVES: Inflammatory bowel disease (IBD) affects 1-1.4 million people in the
United States. IBD affects people during their economically productive adult lives
and can have potential economic impact of IBD on productivity loss in the work-
force.We compared risk, absenteeism, andmedical/pharmacy costs for employees
with IBD and fivemost prevalent chronic conditions.METHODS:Health-risk infor-
mation and self-reported illness days using health-risk assessment (HRA) data
were examined and direct Healthcare costs (medical and pharmacy) using claims
data for employees, retirees, and their adult dependents of a large self-insured
employer were compared from 2002-2006 among individuals with IBD and five
most prevalent chronic conditions; asthma, coronary artery disease/congestive
heart failure (CAD/CHF), diabetes, hypertension, chronic obstructive pulmonary
disease (COPD). RESULTS: 44 individuals with IBD were identified. The IBD cohort
had moderate health-risk score (2.6/5) which was comparable to individuals with
asthma (2.8/5), CHF (2.9), hypertension (2.6) and lower than diabetes (3.2/5) and
COPD (3.4/5). Whereas, higher proportion (31.8%) of individuals with IBD had 5
illness days per year as compared with individuals with asthma (31.8%), CAD/CHF
(25.9%), hypertension (20.4%), diabetes (28.4%), and COPD (33%). Annual direct
healthcare costs were higher for individuals with IBD ($24,911) as compared to
individuals CAD/CHF ($22,916), and hypertension ($18,632), and lower as compared
to individuals with asthma ($25,814), diabetes ($28,035), and COPD ($38,839).
CONCLUSIONS: Individuals with IBD have similar health-risks but higher illness
days, and direct healthcare costs as compared to the individuals with five most
prevalent chronic conditions. IBD is a high costs and lost productivity driver for
employers. Population health based programs that engage employees in appropri-
ately managing their chronic conditions can help employers reduce health-risks,
improve productivity, and may help reduce healthcare costs as well.
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OBJECTIVES: To compare the direct medical costs and services by point of service
(PoS) and the prescription drug (Rx) costs and services for persons with Hepatitis-C
(HCV) who are treated (HCV-Tx) and not-treated (HCV-noTx). METHODS: A retro-
spective analysis using the HCMS Research Reference database, which represents
multiple US-based employers and contains employee data from 2001-2Q2007. This
analysis compared the annual direct medical costs and services for healthcare by
PoS, and Rx costs and services for HCV employees with and without Tx. ICD-9
Codes were used to identify employees with HCV. All subjects were required to
have1 month of eligibility. The first ribavirin, interferon or peginterferon Rx was
the HCV-Tx cohort’s index date. The HCV-noTx cohort was assigned the average
index date (by company) of the HCV-Tx cohort. Two-part regression models were
used to compare the cohorts adjusting for demographics, job-related variables,
eligibilitymonths, and Charlson Comorbidity Index. PoS Locations include: doctors
office (MD), inpatient hospital (IN), outpatient hospital or clinic (OUT), emergency
department (ED), laboratory (LAB), and other. Annual Rx costs and services were
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